– Klinische Daten aus dem TIGIT-Programm werden für 2024 erwartet, darunter zwei Phase-II-Studien zur Bewertung von Belrestotug + Dostarlimab bei NSCLC und HNSCC in der Erstlinie
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Italfarmaco Announces U.S. FDA Grants Fast Track Designation to Givinostat in Treatment of Polycythemia Vera - May 6, 2025
- Akropolis Group has mandated Citigroup Global Markets Europe AG, ING Bank N.V. and Skandinaviska Enskilda Banken AB (publ) to coordinate bond issuance process and commence meetings with investors - May 6, 2025
- Announcement concerning large shareholders under the Danish Capital Markets Act - May 6, 2025
